Cargando…

Release of cervical muscular tension improved severe pruritus in moderate-to-severe atopic dermatitis: A case series

Detalles Bibliográficos
Autores principales:	Hosono, Shusaku, Fujita, Koji, Nimura, Akimoto, Akita, Keiichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256226/ https://www.ncbi.nlm.nih.gov/pubmed/32490112 http://dx.doi.org/10.1016/j.jdcr.2020.03.018

Ejemplares similares

Release of Cervical Muscle Tension Improves Psychological Stress and Symptoms of Moderate-to-Severe Atopic Dermatitis: a Case Series with 20 Patients
por: Hosono, Shusaku, et al.
Publicado: (2022)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus
por: Teresiak-Mikołajczak, Ewa, et al.
Publicado: (2013)

Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis
por: Maudinet, Adrien, et al.
Publicado: (2019)

Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD
por: Hall, Rebecca, et al.
Publicado: (2021)

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
por: Yosipovitch, G., et al.
Publicado: (2019)

Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD
por: Hall, Rebecca, et al.
Publicado: (2021)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Association of Moderate–Severe Atopic Dermatitis with Dental Anomalies
por: Tan, Sean Y., et al.
Publicado: (2022)

Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis
por: Smith, Mary Patricia, et al.
Publicado: (2019)

JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients
por: Shahriari, Neda, et al.
Publicado: (2023)

Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
por: Hulshof, Lies, et al.
Publicado: (2018)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
por: Saporito, Rachael C., et al.
Publicado: (2016)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Neuroimmunological Mechanism of Pruritus in Atopic Dermatitis Focused on the Role of Serotonin
por: Kim, Kwangmi
Publicado: (2012)

The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus
por: Rerknimitr, Pawinee, et al.
Publicado: (2017)

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
por: Xu, Xinghua, et al.
Publicado: (2017)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients
por: Achten, Roselie E., et al.
Publicado: (2022)

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
por: Soehoel, Anders, et al.
Publicado: (2022)

Increased Risk of Renal Malignancy in Patients with Moderate to Severe Atopic Dermatitis
por: Oh, Jongwook, et al.
Publicado: (2023)

Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)

Transcutaneous Slowly Depolarizing Currents Elicit Pruritus in Patients with Atopic Dermatitis
por: RUKWIED, Roman, et al.
Publicado: (2020)

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Pathomechanism of Pruritus in Psoriasis and Atopic Dermatitis: Novel Approaches, Similarities and Differences
por: Kaczmarska, Agnieszka, et al.
Publicado: (2023)

Dupilumab for the treatment of alopecia areata in children with atopic dermatitis
por: Cho, Sung Kyung, et al.
Publicado: (2021)

Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS)
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies
por: Kabashima, K., et al.
Publicado: (2021)

Anatomical study for elucidating the stabilization mechanism in the trapeziometacarpal joint
por: Norose, Mio, et al.
Publicado: (2022)

Review of Prominent Cytokines as Superior Therapeutic Targets for Moderate-to-Severe Atopic Dermatitis
por: Hassan, Zaira, et al.
Publicado: (2020)

Dupilumab therapy following JAK inhibitor withdrawal in moderate–severe atopic dermatitis
por: Kiely, Lisa, et al.
Publicado: (2022)

Effect of Dupilumab on Sexual Desire in Adult Patients with Moderate to Severe Atopic Dermatitis
por: Napolitano, Maddalena, et al.
Publicado: (2022)

Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
por: Ferrucci, Silvia, et al.
Publicado: (2023)

The ability of biomarkers to assess the severity of atopic dermatitis
por: Nakahara, Takeshi, et al.
Publicado: (2023)

Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate‐to‐severe hidradenitis suppurativa
por: Molinelli, Elisa, et al.
Publicado: (2022)

Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis
por: Jee, Sue-Jung, et al.
Publicado: (2011)

Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis
por: Awosika, Olabola, et al.
Publicado: (2018)

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey
por: Sastre, Joaquín, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5rins9kpajvnco9vehcr1bstfo